KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Depreciation & Amortization (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Accumulated Depreciation & Amortization for 15 consecutive years, with $91.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 13.86% to $91.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $91.6 million, a 13.86% increase, with the full-year FY2025 number at $91.6 million, up 13.86% from a year prior.
  • Accumulated Depreciation & Amortization was $91.6 million for Q4 2025 at Supernus Pharmaceuticals, up from $66.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $91.6 million in Q4 2025 to a low of $600000.0 in Q3 2021.
  • A 5-year average of $20.8 million and a median of $2.8 million in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: crashed 99.05% in 2024, then skyrocketed 10991.17% in 2025.
  • Supernus Pharmaceuticals' Accumulated Depreciation & Amortization stood at $32.6 million in 2021, then tumbled by 90.8% to $3.0 million in 2022, then fell by 16.67% to $2.5 million in 2023, then surged by 3116.56% to $80.4 million in 2024, then rose by 13.86% to $91.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Accumulated Depreciation & Amortization are $91.6 million (Q4 2025), $66.5 million (Q3 2025), and $1.1 million (Q2 2025).